Recombinant FOXA1 Monoclonal Antibody (AN301524L)
For research use only.
| Verified Samples |
Verified Samples in WB: HeLa, HepG2, Mouse lung, Rat lung Verified Samples in IHC: Human breast cancer Verified Samples in FCM: HepG2 |
| Dilution | WB 1:500-1:2000, IHC 1:200-1:1000, FCM 1:50-1:100 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, Rat, Mouse |
| Applications | WB, IHC, FCM |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human FOXA1 fragment |
| Abbre | FOXA1 |
| Synonyms | FOXA, FOXA1, HNF3A, TCF3A |
| Swissprot | |
| Calculated MW | 49 kDa |
| Observed MW |
52 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Epigenetics and Nuclear Signaling |
| Clone No. | A223 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Forkhead transcription factor (FOXA1) is a pioneering factor in the development of some organs and certain cancers. It opens tight chromatin by interacting with nucleosomal core histones. FOXA1 can bind to cis-acting elements and recruit other transcription factors to induce transcription. FOXA1 is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues, and participates in the development of a variety of endoderm-derived organ systems, such as liver, pancreas, lung and prostate. FOXA1 is related to many diseases and plays a role in hormone-dependent diseases such as breast cancer and prostate cancer. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
